Despite a variety of diverse obstacles in the past few years, the life sciences and biotechnology industry in the United States and abroad has continued to prosper.
Our sophisticated and nationally recognized practice serves a diverse group of clients, including corporations, universities and entrepreneurs with national and global interests in the healthcare, biotechnology, pharmaceutical, energy and environmental industries, to name a few.
The skill and capabilities of our biotechnology practice have been recognized by the National Institutes of Health (NIH) in 2009 when we were one of only six law firms selected to secure protection of biotechnology inventions from inventors at all NIH institutions. In addition, Intellectual Asset Management magazine, and its patent ratings partner Ocean Tomo, ranked our team second in the country in 2010 in securing the highest-quality patents in the healthcare sector.*
We have achieved this success on behalf of our clients by:
- Aligning the patent prosecution process with our client's core business strategies,
- Directing patent investment on inventions most likely to be valuable in the relevant market, and
- With patent application preparation and prosecution focused on securing patents, having excellent monetization and enforcement value over the life of the patent.
We also advise on investing in life science companies, often a risky proposition. Prudent investing requires an in-depth understanding of the intellectual property landscape for target companies.
Our lawyers have long served clients by building patent assets of value and assessing freedom-to-practice technology. We also help investors make better investment decisions by providing a clear vision of intellectual property opportunities and risks.
* To read the full article, please click here. This article first appeared in Intellectual Asset Management magazine, issue 40. To view the magazine in full, please go to www.iam-magazine.com.